ProfileGDS5678 / 1444754_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 32% 31% 34% 24% 30% 32% 30% 36% 32% 30% 39% 30% 34% 33% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7577432
GSM967853U87-EV human glioblastoma xenograft - Control 22.6942231
GSM967854U87-EV human glioblastoma xenograft - Control 32.7786534
GSM967855U87-EV human glioblastoma xenograft - Control 42.5184824
GSM967856U87-EV human glioblastoma xenograft - Control 52.6335630
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7968232
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7428330
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8153536
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7078532
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6778230
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8970239
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6565130
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7672534
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7481933